We are pleased to invite you to attend “Para-Injecto 2016 - The world of Parenterals and Injectables” conference and training to be held on 20-21 October 2016 in Hyderabad. The conference will be unveiling the challenges and exploring solutions in Formulation & Development, Manufacturing, packaging, Quality and Regulatory aspects of Parenterals and Injectables. The Para-injecto conference is a perfect platform to showcase and discuss with the industry leaders the recent advances, latest technology and alternative strategies that are flexible and cost-effective to develop and manufacture Parenterals & Injectables.
Renowed Industry Leaders, Regulatory Experts, Academia, Solutions providers and Manufacturers from Asia and across the globe will be a part of this mega conference and will be sharing their experience of Parenterals and Injectables There will be ample of opportunity to meet & interact with speakers, industry peers, regulators, Exhibitors and industry leaders during the Networking breaks and interactive discussions.
Unveiling the Challenges & Exploring the Practical Solutions Learn Latest trends, current best practices and future expectation from industry thought leaders through presentation, case studies and Panels discussions during the conference sessions.
In addition to the conference, training course and workshop will be conducted
on second day, 7th October 2016.
The topics to be covered on the workshops:
Terumo Corporation is one of the world’s leading medical technology companies and operates in more than 160 nations. Terumo, founded in 1921, develops, manufactures and distributes a broad range of world-class medical devices including the supply of drug delivery/injection devices to the pharmaceutical industry. Terumo Pharmaceutical Solutions (TPS) offers the pharmaceutical and biotechnology industry unique solutions in medical technology. In addition to offering our valued products, our specialized team also provides customized and dedicated solutions designed to meet your specific requirements.
They are the AptarGroup business segment dedicated to the evolving needs of biotechnology, healthcare and pharmaceutical companies with innovative drug delivery solutions. With a strong focus on leveraging innovation to provide patient-focused solutions, we allocate 5% of annual revenue to research and development.